ASX Announcement

Medibio Limited – 7 March 2019



Medibio's Corporate Health Product ilumen[™] Successfully Completes First Commercial Program

Highlights:

- First commercial implementation of ilumenTM a success.
- Voluntary participation of 1,675 out of 7,500 employees (22% of workforce).
- Exceeded the 600 participants of previous programs.
- Program completed seamlessly, efficiently and trouble-free.
- Medibio selectively considering unsolicited approaches from large global employer and employee benefits organisations.

Melbourne, Australia and Minneapolis, MN – 7 March 2019: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCQB: MDBIF), a mental health technology company announces results of the latest release of its corporate health product, ilumenTM, with a large Australian employer.


ilumen™ is unique to the corporate health market as it integrates proprietary objective biometrics with subjective assessments. Users can access and monitor their mental well-being data from their personal devices, measuring and tracking biometrics through the use of wearable technology over a period of time.

Under the terms of the contract ilumen[™] was offered, on a voluntary basis, to nearly 7,500 personnel throughout Australia over a six-week period commencing October 2018.

This program was the first commercial implementation of ilumenTM, Medibio's second Corporate Health product. The Company is pleased to report on the results of the program, including the performance of ilumenTM.

- Of the nearly 7,500 personnel informed about the availability of ilumen[™], 1,675 (22%) registered for the program.
- ilumen[™] identified 26% of participants that experienced symptoms of depression or anxiety in the moderate to severe range, which is broadly consistent with population norms. This result equates to more than 40,000¹ hours of productivity lost per year due to depression in the cohort, demonstrating some of the benefits that ilumen[™] provides to employers and employees.

ASX Announcement





- Typical feedback received from those with elevated scores was:
 - "Thank you for your email. I have started seeing a psychologist and I showed her my results yesterday. I have another appointment with her on Monday and today I'm going to see my GP to seek some kind of treatment further to seeing a psychologist and practicing techniques."
 - "Thank you for your concern, following on from this I have booked in some time with the Employee Assistance Program."

"We are particularly pleased with the participation rate of ilumen[™], as it was voluntary," said Jennifer Solitario Senior Vice President of Corporate Health. "It demonstrates the changing attitude of employers and employees to mental health and well-being, both in terms of awareness and more importantly, the desire to do something about it. The de-identified aggregate results provided to the employer allows them to support improved employee well-being and productivity. We are now in discussions with the employer regarding ongoing utilisation of ilumen[™]."

Solitario goes on to say, "We are pleased to commence the previously announced AIAA program by the middle of March and continue to consider unsolicited approaches from major global companies, the implementation of which will have regard to the Company's limited resources at this time."

- ENDS -

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers comprehensive mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.asx.com.au.

Further Information:	Website: www.medibio.com.au
Medibio Media Enquiries:	Australian Investor Enquiries:
Kristi Hamilton	Peter Taylor
Senior Manager, Marketing Communications	NWR Communications
Medibio Limited	peter@nwrcommunications.com.au
kristi.hamilton@medibio.com.au	T: +61 (0) 412 036 231
T: +1 952 232 0934	

Sources:

 Greenberg, P, Fournier, A, Sistiksy, T, Pike, C & Kessler, R. (2015). <u>The economic burden of adults with major depressive</u> disorder in the United States (2005 and 2010). Journal of Clinical Psychiatry. Retrieved 6 March 2019